OOIR: Observatory of International Research

Papers

(The H4-Index of JCO Precision Oncology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer	69
Pyroptosis-Derived Long Noncoding RNA Profiles Reveal a Novel Signature for Evaluating the Prognosis of Patients With Lung Adenocarcinoma	56
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence	55
Abscopal Effect of Radiation on Liver Metastases of Poorly Differentiated Parotid Carcinoma	52
Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases	51
Role of Apparent Diffusion Coefficient Map-Based First- and High-Order Radiomic Features for the Discrimination of Sacral Chordomas and Chondrosarcomas With Overlapping Conventional Imaging Features	51
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer	49
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Explora	49
Implementation of Cancer Genomics in the United States: Views of Payers and Other Stakeholders on Challenges and the Role of Payers in Solutions	48
Reply to H. Seibert et al	47
Novel OncogenicPDGFRBVariant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring	46
BRCA1/2Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling Outcomes	45
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma	43
Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study	41
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group	38
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy	36
Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing	36
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary	36
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer	35
Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non–Small-Cell Lung Cancer	35
Novel Adjuvant Targeted Approach for PTEN-Mutated Choroid Plexus Carcinoma in Adults: Case Report and Literature Review	35
Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project	34
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies	34
Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block	34
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome	34

Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy	33
GermlineSMARCA4Deletion as a Driver of Uterine Cancer: An Atypical Presentation	33
Nodular Regenerative Hyperplasia of the Liver Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor in a Patient With Metastatic Renal Cell Carcinoma	32
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers	31
Clinical Trial Diversity: A Bend in the Arc Toward Justice	31
Germline Pathogenic Variants in Patients With Pancreatic and Periampullary Cancers	30
Dabrafenib for Pilocytic Astrocytoma With BRAF V599ins	30
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI	30